Rocket Pharmaceuticals (RCKT) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
X4 Pharmaceuticals (XFOR) has outperformed Rocket Pharmaceuticals (RCKT) over the past year, losing 16.0% versus a loss of 22.4%. Over five years, RCKT leads with a -90.6% price change compared with -98.2% for XFOR. Rocket Pharmaceuticals is the larger company by market cap ($289.8 million vs $285.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RCKT | XFOR |
|---|---|---|
| Share price | $2.64 | $2.88 |
| Market cap | $289.80M | $285.05M |
| 1-day change | +0.38% | +3.05% |
| YTD return | -25.07% | -30.25% |
| 1-year return | -22.42% | -15.96% |
| 5-year return | -90.58% | -98.22% |
| P/E ratio (TTM) | — | 143.75 |
| EPS (TTM) | $-0.17 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.45 | $4.83 |
| 52-week low | $2.42 | $2.70 |
| Distance from 52-week high | -51.56% | -40.48% |
| Analyst consensus | buy | none |
| Avg. price target upside | +221.97% | +303.48% |
| Average volume | 1.67M | 849.58K |
| Shares outstanding | 109.77M | 99.15M |
| Employees | 202 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
RCKT vs XFOR FAQ
Which is bigger, Rocket Pharmaceuticals or X4 Pharmaceuticals?
Rocket Pharmaceuticals (RCKT) is larger, with a market capitalization of $289.80M compared with $285.05M for X4 Pharmaceuticals (XFOR).
Which stock has performed better over the past year, RCKT or XFOR?
XFOR returned -15.96% over the past 12 months, compared with -22.42% for RCKT (price return, excluding dividends). Past performance does not predict future results.
Are Rocket Pharmaceuticals and X4 Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Rocket Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for X4 Pharmaceuticals.